Severe Thrombocytopenia Is Associated With Bleeding in Hepatocellular Carcinoma Patients Receiving Antiangiogenic Therapy
Portal Hypertension & Cirrhosis · 2026-06 · 5 (2) · 140-149
DOI: 10.1002/poh2.70044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Portal Hypertension & Cirrhosis, online erschienen am 31.03.2026. Verfasst von Jun Tie und 8 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aims
Thrombocytopenia and antiangiogenic agents increase bleeding risk in hepatocellular carcinoma (HCC). We aimed to identify a baseline platelet threshold for bleeding risk stratification.
Methods
This single‐center retrospective cohort included 489 HCC patients treated with antiangiogenic agents from January 2018 to June 2022 without prophylactic platelet‐increasing interventions. Bleeding events were defined using International Society on Thrombosis and Hemostasis criteria. Fine and Gray competing‐risk models were used to explore platelet‐count cutoffs associated with bleeding. Associations were assessed with logistic regression and Chi‐square/Fisher's exact tests, adjusting for key confounders including high‐risk esophageal and gastric varices (EGV). Severe thrombocytopenia was defined as baseline platelets < 50 × 10 9 /L.
Results
The bleeding rate was 11.0% (54/489). Baseline platelet counts were lower in patients with bleeding than in those without (median 116 × 10 9 /L vs. 140 × 10 9 /L; p = 0.015). Bleeding was more frequent with severe thrombocytopenia (< 50 × 10 9 /L) than with platelet counts ≥ 50 × 10 9 /L (22.9% [8/35] vs. 10.1% [46/454]; p = 0.021). Although platelet count < 50 × 10 9 /L was associated with bleeding in univariable analyses, it was not independently predictive after multivariable adjustment; high‐risk EGV remained the dominant independent risk factor.
Conclusion
Baseline platelets < 50 × 10 9 /L is a useful risk‐stratification marker (not an independent predictive biomarker) for bleeding during antiangiogenic therapy in HCC, and this threshold should be interpreted alongside variceal risk assessment, particularly in patients with high‐risk EGV.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Tie, J., Liu, Z., Yuan, X., Li, K., Niu, J., Xu, J., Xu, L., Shi, Y., & Yue, S. (2026). Severe Thrombocytopenia Is Associated With Bleeding in Hepatocellular Carcinoma Patients Receiving Antiangiogenic Therapy. Portal Hypertension & Cirrhosis, 5(2), 140-149. https://doi.org/10.1002/poh2.70044
Vancouver
Tie J, Liu Z, Yuan X, Li K, Niu J, Xu J, et al. Severe Thrombocytopenia Is Associated With Bleeding in Hepatocellular Carcinoma Patients Receiving Antiangiogenic Therapy. Portal Hypertension & Cirrhosis. 2026;5(2):140-149. doi:10.1002/poh2.70044
BibTeX
@article{Tie2026,
author = {Tie, Jun and Liu, Zhengcai and Yuan, Xulong and Li, Kai and Niu, Jing and Xu, Jiao and Xu, Li and Shi, Yongquan and Yue, Shuqiang},
title = {Severe Thrombocytopenia Is Associated With Bleeding in Hepatocellular Carcinoma Patients Receiving Antiangiogenic Therapy},
journal = {Portal Hypertension & Cirrhosis},
year = {2026},
volume = {5},
number = {2},
pages = {140--149},
doi = {10.1002/poh2.70044}
}
EUVIMED